Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
about
Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment.Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma.Cytokine release syndrome.Hemofiltration Successfully Eliminates Severe Cytokine Release Syndrome Following CD19 CAR-T-Cell Therapy
P2860
Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
@en
Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
@nl
type
label
Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
@en
Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
@nl
prefLabel
Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
@en
Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
@nl
P2093
P2860
P1433
P1476
Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
@en
P2093
Adrian Bot
Antoni Ribas
Marc Better
Margo R Roberts
Zachary J Roberts
P2860
P356
10.1080/10428194.2017.1387905
P577
2017-10-23T00:00:00Z